STI Affinity Chromatography for Modified Factor Xa Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The limitations of anticoagulant therapy include a bleeding risk and the inability to rapidly reverse anticoagulant activity, necessitating the development of specific and effective antidotes, particularly for modified factor Xa proteins which pose challenges in purification due to their binding characteristics.
Innovation Solution
The use of a soybean trypsin inhibitor (STI)-based affinity chromatograph with an elution buffer containing a competitive agent like arginine, along with optional salts and detergents, to effectively purify serine proteases such as modified factor Xa proteins, allowing for efficient separation and recovery without inactivating the proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used for modified factor Xa proteins, then the purification process is simple and familiar, but the purification effectiveness is poor due to altered binding characteristics of modified proteins
Solution Approach 1:
The patent changes the binding parameters of the purification system by using STI affinity chromatography instead of conventional methods. The modified factor Xa proteins retain their ability to bind to STI despite modifications, allowing effective purification through parameter-based separation rather than relying on conventional purification approaches that fail with modified proteins.
2Productivity
If strong elution conditions are used to disrupt STI-protease interaction, then purification efficiency is improved, but protein biological activity may be lost
Solution Approach 1:
The patent uses pH gradient elution to gradually change the binding conditions rather than applying strong denaturing conditions abruptly. By adjusting pH from neutral to acidic ranges, the method disrupts STI-protease interactions progressively, allowing efficient elution while maintaining protein biological activity through controlled parameter changes.
3Reliability
If modified derivatives of factor Xa are used as antidotes, then the antidote effectiveness is improved, but the purification difficulty increases due to modified binding characteristics
Solution Approach 1:
The patent uses STI as an intermediary molecule that mediates the purification of modified factor Xa proteins. The STI affinity chromatography system acts as a bridge that exploits the retained binding capability of modified proteins, enabling their purification despite the modifications that make conventional methods ineffective.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the purification of serine proteases, including modified factor Xa derivatives, by disrupting the interaction between the STI and the protease, resulting in a highly effective and safe purification process that maintains the biological activity of the proteins.
Implementation Method 1
loading the serine protease to a soybean trypsin inhibitor (STI)-based affinity chromatograph
Implementation Method 2
eluting the serine protease with an elution buffer comprising a competitive agent, that disrupts interaction between the STI and the serine protease which is arginine
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed herein are methods and kits for purifying a serine protease. The methods entail loading the serine protease to a soybean trypsin inhibitor (STI) based affinity chromatograph, and eluting the serine protease with an elution buffer comprising an agent that disrupts interaction between the STI and the serine protease